Reduced BDNF mRNA Expression in the Parkinson's Disease Substantia Nigra

Brain-derived neurotrophic factor (BDNF) has potent effects on survival and morphology of dopaminergic neurons and thus its loss could contribute to death of these cells in Parkinson's disease (PD). In situ hybridization revealed that BDNF mRNA is strongly expressed by dopaminergic neurons in control substantia nigra pars compacta (SNpc). In clinically and neuropathologically typical PD, SNpc BDNF mRNA expression is reduced by 70% (P = 0.001). This reduction is due, in part, to loss of dopaminergic neurons which express BDNF. However, surviving dopaminergic neurons in the PD SNpc also expressed less BDNF mRNA (20%, P = 0.02) than their normal counterparts. Moreover, while 15% of control neurons had BDNF mRNA expression >1 SD below the control mean, twice as many (28%) of the surviving PD SNpc dopaminergic neurons had BDNF mRNA expression below this value. This 13% difference in proportions (95% CI 8-17%, P < or = 0.000001) indicates the presence of a subset of neurons in PD with particularly low BDNF mRNA expression. Moreover, both control and PD neurons displayed a direct relationship between the density of BDNF mRNA expression per square micrometer of cell surface and neuronal size (r(2) = 0.93, P </= 0.00001) which was lost only in PD neurons expressing the lowest levels of BDNF mRNA. If BDNF is an autocrine/paracrine factor for SNpc dopaminergic neurons, loss of BDNF-expressing neurons may compromise the well-being of their surviving neighbors. Moreover, neurons expressing particularly low levels of BDNF mRNA may be those at greatest risk of injury in PD and possibly the trigger for the degeneration itself.

[1]  H. Ichinose,et al.  Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease , 1999, Neuroscience Letters.

[2]  J. Simons,et al.  Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. , 1999, Biochemical and biophysical research communications.

[3]  D. Chuang,et al.  Nuclear Translocation of Glyceraldehyde‐3‐Phosphate Dehydrogenase Isoforms During Neuronal Apoptosis , 1999, Journal of neurochemistry.

[4]  Geoffrey A. Donnan,et al.  Activated Macrophages and Microglia Induce Dopaminergic Sprouting in the Injured Striatum and Express Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor , 1999, The Journal of Neuroscience.

[5]  E. Hirsch,et al.  Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. , 1999, Neuroreport.

[6]  Kristina D. Micheva,et al.  β‐Actin is confined to structures having high capacity of remodelling in developing and adult rat cerebellum , 1998, The European journal of neuroscience.

[7]  C. Altar,et al.  Neurotrophin trafficking by anterograde transport , 1998, Trends in Neurosciences.

[8]  Y. Agid,et al.  Tyrosine kinase B messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study , 1998, Neuroscience.

[9]  G. Donnan,et al.  Expression of Brain-Derived Neurotrophic Factor and TrkB Neurotrophin Receptors after Striatal Injury in the Mouse , 1997, Experimental Neurology.

[10]  G. Donnan,et al.  Expression of glial cell line-derived neurotrophic factor (GDNF) mRNA following mechanical injury to mouse striatum. , 1997, Neuroreport.

[11]  I. Mcquarrie,et al.  Axonal regrowth upregulates β-actin and Jun D mRNA expression , 1996 .

[12]  G. Donnan,et al.  Dopaminergic responses to striatal damage , 1996, Journal of the Neurological Sciences.

[13]  B. Hoffer,et al.  Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.

[14]  M. Beal,et al.  Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration. , 1996, Cell transplantation.

[15]  S. Wiegand,et al.  BDNF Enhances the Functional Reinnervation of the Striatum by Grafted Fetal Dopamine Neurons , 1996, Experimental Neurology.

[16]  C. Mytilineou,et al.  Glial Cell Line‐Derived Neurotrophic Factor Exerts Neurotrophic Effects on Dopaminergic Neurons In Vitro and Promotes Their Survival and Regrowth After Damage by 1‐Methyl‐4‐Phenylpyridinium , 1996, Journal of neurochemistry.

[17]  M. Levivier,et al.  Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[18]  S. Shimohama,et al.  Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. , 1995, Neurosurgery.

[19]  C. Shults,et al.  BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine , 1995 .

[20]  C D Marsden,et al.  Tissue pH as an indicator of mRNA preservation in human post-mortem brain. , 1995, Brain research. Molecular brain research.

[21]  C. Gall,et al.  Dopaminergic neurons in rat ventral midbrain express brain‐derived neurotrophic factor and neurotrophin‐3 mRNAs , 1994, The Journal of comparative neurology.

[22]  G. Donnan,et al.  Surgical damage stimulates proliferation of dopamine uptake sites in normal mouse brain , 1993, Brain Research.

[23]  H. Lagercrantz,et al.  Expression of members of the trk family in the developing postnatal rat brain. , 1993, Brain research. Developmental brain research.

[24]  P. Ernfors,et al.  Molecular cloning of rat trkC and distribution of cells expressing messenger RNAs for members of the trk family in the rat central nervous system , 1992, Neuroscience.

[25]  I. Kanazawa,et al.  Dopaminergic stimulation up‐regulates the in vivo expression of brain‐derived neurotrophic factor (BDNF) in the striatum , 1992, FEBS letters.

[26]  R. Lindsay,et al.  Brain‐Derived Neurotrophic Factor Protects Dopamine Neurons Against 6‐Hydroxydopamine and N‐Methyl‐4‐Phenylpyridinium Ion Toxicity: Involvement of the Glutathione System , 1992, Journal of neurochemistry.

[27]  A. Lees,et al.  What features improve the accuracy of clinical diagnosis in Parkinson's disease , 1992, Neurology.

[28]  C. Gall,et al.  Brain-derived neurotrophic factor and neurotrophin-3 mRNAs are expressed in ventral midbrain regions containing dopaminergic neurons , 1992, Molecular and Cellular Neuroscience.

[29]  J. Cadet,et al.  Sham transplantation protects against 6-hydroxydopamine-induced dopaminergic toxicity in rats: behavioral and morphological evidence , 1991, Brain Research.

[30]  R. Penn,et al.  Putative chromaffin cell survival and enhanced host‐derived TH‐Fiber innervation following a functional adrenal medulla autograft for Parkinson's disease , 1991, Annals of neurology.

[31]  G. Yancopoulos,et al.  BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra , 1991, Nature.

[32]  E. Oldfield,et al.  Long-term evaluation of hemiparkinsonian monkeys after adrenal autografting or cavitation alone. , 1990, Journal of neurosurgery.

[33]  L. Reichardt,et al.  Molecular cloning of a human gene that is a member of the nerve growth factor family. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Y. Agid,et al.  Does adrenal graft enhance recovery of dopaminergic neurons in Parkinson's disease? , 1990, Annals of neurology.

[35]  W. Gibb Neuropathology in movement disorders. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[36]  J. Kordower,et al.  Adrenal medullary autografts into the basal ganglia of Cebus monkeys: Injury-induced regeneration , 1988, Experimental Neurology.

[37]  Haruhiko Akiyama,et al.  Rate of cell death in parkinsonism indicates active neuropathological process , 1988, Annals of neurology.

[38]  D. Gash,et al.  Adrenal medulla grafts enhance recovery of striatal dopaminergic fibers. , 1987, Science.

[39]  S H Appel,et al.  A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and alzheimer disease , 1981, Annals of neurology.

[40]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[41]  A. Kupsch,et al.  Potential of neurotrophic factors in therapy of Parkinson's disease. , 1996, Journal of neural transmission. Supplementum.

[42]  Ward Cd,et al.  Research diagnostic criteria for Parkinson's disease. , 1990 .